Literature DB >> 15677577

Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis.

Salvatore Novo1, Stefania Basili, Rosalba Tantillo, Angela Falco, Valentina Davì, Giuseppina Novo, Egle Corrado, Giovanni Davì.   

Abstract

BACKGROUND AND
PURPOSE: We investigated whether soluble CD40L (sCD40L) may predict the risk of cardiovascular (CV) events in patients with asymptomatic carotid plaques.
METHODS: Forty-two patients with asymptomatic low-grade carotid stenosis (ALCS) and 21 controls without any carotid stenosis were enrolled. All subjects had at least a major cardiovascular risk factor (CRF). Plasma levels of C-reactive protein (CRP), IL-6, and sCD40L were measured. Subjects were reviewed every 12 months (median follow-up, 8 years).
RESULTS: ALCS patients had higher (P<0.0001) CRP, IL-6, and sCD40L than controls. Fourteen patients experienced a CV event. Cox regression analysis showed that only high sCD40L levels (P=0.003) independently predicted cardiovascular risk.
CONCLUSIONS: High levels of sCD40L may predict the risk of CV events in ALCS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15677577     DOI: 10.1161/01.STR.0000154878.58398.14

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  12 in total

Review 1.  CD40/CD40L system and vascular disease.

Authors:  F Santilli; S Basili; P Ferroni; G Davì
Journal:  Intern Emerg Med       Date:  2007-11-28       Impact factor: 3.397

Review 2.  Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data.

Authors:  Gaurav Sharma; Jeffrey S Berger
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

3.  Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury.

Authors:  P R Tuinman; M C Gerards; G Jongsma; A P Vlaar; L Boon; N P Juffermans
Journal:  Clin Exp Immunol       Date:  2011-05-23       Impact factor: 4.330

Review 4.  The promise and potential pitfalls of serum biomarkers for ischemic stroke and transient ischemic attack.

Authors:  Matthew B Jensen; Marcus R Chacon; Justin A Sattin; Aitziber Aleu; Patrick D Lyden
Journal:  Neurologist       Date:  2008-07       Impact factor: 1.398

5.  β-Thromboglobulin and incident cardiovascular disease risk: The Atherosclerosis Risk in Communities study.

Authors:  Yasuhiko Kubota; Alvaro Alonso; Aaron R Folsom
Journal:  Thromb Res       Date:  2017-05-17       Impact factor: 3.944

6.  Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction.

Authors:  Mohamed Abo-Aly; Bennet George; Elica Shokri; Lakshman Chelvarajan; Mohamed El-Helw; Susan S Smyth; Ahmed Abdel-Latif; Khaled Ziada
Journal:  J Thromb Thrombolysis       Date:  2020-11-30       Impact factor: 2.300

7.  Association between Serum Soluble CD154 Levels and Mortality in Patients with Malignant Middle Cerebral Artery Infarction.

Authors:  Leonardo Lorente; María M Martín; Agustín F González-Rivero; Luis Ramos; Mónica Argueso; Juan J Cáceres; Jordi Solé-Violán; Alejandro Jiménez; Juan M Borreguero-León
Journal:  Int J Mol Sci       Date:  2015-05-28       Impact factor: 5.923

8.  CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.

Authors:  Anthony Shock; Linda Burkly; Ian Wakefield; Christopher Peters; Ellen Garber; Janine Ferrant; Frederick R Taylor; Lihe Su; Yen-Ming Hsu; David Hutto; Ali Amirkhosravi; Todd Meyer; John Francis; Sarah Malcolm; Martyn Robinson; Derek Brown; Stevan Shaw; Roland Foulkes; Alastair Lawson; Olivier Harari; Timothy Bourne; Alison Maloney; Neil Weir
Journal:  Arthritis Res Ther       Date:  2015-09-03       Impact factor: 5.156

9.  Therapeutic effects of anti-CD154 antibody in cynomolgus monkeys with advanced rheumatoid arthritis.

Authors:  Eun Wha Choi; Kyo Won Lee; Hyojun Park; Hwajung Kim; Jong Hyun Lee; Ji Woo Song; Jehoon Yang; Yeongbeen Kwon; Tae Min Kim; Jae Berm Park; Sungjoo Kim
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

10.  IL-6, PF-4, sCD40 L, and homocysteine are associated with the radiological progression of cerebral small-vessel disease: a 2-year follow-up study.

Authors:  Jacek Staszewski; Renata Piusińska-Macoch; Bogdan Brodacki; Ewa Skrobowska; Adam Stępień
Journal:  Clin Interv Aging       Date:  2018-06-19       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.